Literature DB >> 18718746

Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity.

C Dall'Asta1, P Vedani, P Manunta, P Pizzocri, M Marchi, M Paganelli, F Folli, A E Pontiroli.   

Abstract

BACKGROUND AND AIMS: Several mechanisms are probably involved in obesity-related hypertension. This study was aimed to investigate the effect of significant weight loss on blood pressure and plasma renin activity (PRA) and aldosterone levels, other then on metabolic profile, in normotensive and hypertensive obese subjects. METHODS AND
RESULTS: Forty hypertensive and 55 normotensive obese subjects were studied under basal conditions and again 1 year after significant weight loss obtained through laparoscopic adjustable gastric banding (LAGB). Weight, waist circumference, blood glucose, insulin, electrolytes (Na and K), lipids and supine and upright PRA and aldosterone were evaluated. All parameters evaluated improved, except for total cholesterol, and electrolytes that did not change. Blood pressure decreased in hypertensive subjects, with a concordant decrease in PRA and supine aldosterone levels, not observed in normotensive patients.
CONCLUSION: Weight loss is associated with reduction of blood pressure and of PRA and aldosterone levels in obese hypertensive subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718746     DOI: 10.1016/j.numecd.2008.06.001

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  20 in total

Review 1.  Effect of exercise training on the renin-angiotensin-aldosterone system in healthy individuals: a systematic review and meta-analysis.

Authors:  Karla Goessler; Marcos Polito; Véronique Ann Cornelissen
Journal:  Hypertens Res       Date:  2015-09-24       Impact factor: 3.872

Review 2.  A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.

Authors:  J B Byrd; R D Brook
Journal:  J Hum Hypertens       Date:  2013-05-23       Impact factor: 3.012

Review 3.  Aldosterone and cardiovascular risk.

Authors:  Bruno Vogt; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

Review 4.  The renin-angiotensin-aldosterone system and glucose homeostasis.

Authors:  James Matthew Luther; Nancy J Brown
Journal:  Trends Pharmacol Sci       Date:  2011-08-29       Impact factor: 14.819

5.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

6.  Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL).

Authors:  Yewei Xing; William E Rainey; John W Apolzan; Omar L Francone; Ruth B S Harris; Wendy B Bollag
Journal:  Endocrinology       Date:  2011-12-20       Impact factor: 4.736

Review 7.  Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Wendy B Bollag
Journal:  J Endocrinol       Date:  2016-12-02       Impact factor: 4.286

8.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 9.  Drug mechanisms to help in managing resistant hypertension in obesity.

Authors:  Pieter M Jansen; Jan A H Danser; Wilko Spiering; Anton H van den Meiracker
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 10.  Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Authors:  James R Sowers; Adam Whaley-Connell; Murray Epstein
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.